Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Mequitazine (Primary)
- Indications Grass pollen hypersensitivity
- Focus Therapeutic Use
- 02 Jun 2011 New trial record